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Abstract
Background: Acute lung injury complicates approximately 25-30% of subjects undergoing oesophagectomy.
Experimental studies suggest that treatment with beta agonists may prevent the development of acute lung injury
by decreasing inflammatory cell infiltration, activation and inflammatory cytokine release, enhancing basal alveolar
fluid clearance and improving alveolar capillary barrier function.
Methods/Design: The Beta Agonist Lung Injury TrIal (prevention) is a multi-centre, randomised, double blind,
placebo-controlled trial. The aim of the trial is to determine in patients undergoing elective transthoracic
oesphagectomy, if treatment with inhaled salmeterol 100 mcg twice daily started at induction of anaesthesia and
continued for 72 hours thereafter compared to placebo affect the incidence of early acute lung injury and other
clinical, resource and patient focused outcomes. The primary outcome will be the development of acute lung
injury within 72 hours of oesophagectomy. The trial secondary outcomes are the development of acute lung injury
during the first 28 days post operatively; PaO2: FiO2 ratio; the number of ventilator and organ failure free days, 28
and 90 day survival; health related quality of life and resource utilisation. The study aims to recruit 360 patients
from 10 UK centres.
Trial registration number: Current Controlled Trials ISRCTN47481946
Background
Acute Lung Injury (ALI) and the Acute Respiratory Dis-
tress Syndrome (ARDS) occur in response to a wide vari-
ety of insults including traumatic injuries, sepsis, multiple
blood transfusions, pneumonia or aspiration of gastric
contents. The syndrome carries with it significant morbid-
ity [1], a significant risk of death [2], prolonged hospital
stay and high treatment costs [3]. The pathophysiological
changes seen in ALI/ARDS comprise systemic and alveo-
lar inflammation, increased pulmonary vascular perme-
ability and alveolar capillary damage [4]. This causes
flooding of the alveolar space which reduces pulmonary
compliance, interferes with ventilation perfusion matching
and results in hypoxaemia, and acute respiratory failure.
ALI/ARDS complicates approximately 25-30% of sub-
jects undergoing oesophagectomy [5-8]. One lung venti-
lation which is used during the transthoracic approach to
oesophagectomy is implicated in the pathogenesis of
ALI/ARDS [4,9]. It invokes an ischaemia-reperfusion
injury on the deflated lung, whilst the ventilated lung is
exposed to oxygen toxicity and high inflation pressures
which cause ventilator associated lung injury. Thus
patients undergoing oesophagectomy with one lung ven-
tilation are at high risk of developing ALI/ARDS and may
serve as a group of people in whom prophylactic strate-
gies to prevent the development of lung injury may be
considered [10].
Rationale for beta agonists in the prevention of ALI/ARDS
Inflammation
b2 agonists reduce neutrophil sequestration, activation and
inflammatory cytokine production in-vitro and in animal
models of ARDS [11]. In humans, inhaled salmeterol (long
acting b2 agonist) given prior to lipopolysaccharide inhala-
tion reduces neutrophil influx, degranulation and tumour
necrosis factor a release [12]. However in the single centre
randomised controlled trial (BALTI-1), although salbuta-
mol increased circulating neutrophil numbers, it had no
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effect on alveolar neutrophil sequestration, activation or
alveolar cytokine levels [13]. A potential explanation for
this finding is that the administration of a b2 agonist after
the clinical manifestations of ARDS are apparent may be
too late to prevent the early inflammatory influx.
Endothelial / epithelial function
The balance between oedema formation and clearance is
influenced by the degree of alveolar-capillary permeability,
pulmonary capillary hydrostatic and oncotic pressures,
and rate of active alveolar fluid clearance [14]. b2 agonists
may reduce oedema formation through enhancing
alveolar-capillary barrier function. Animal and human stu-
dies [15,16] report improvement in endothelial barrier
function as well as providing epithelial cytoprotection
against infection [11]. In BALTI-1, there was in-vivo evi-
dence of reduced alveolar capillary permeability and
in-vitro evidence of enhanced epithelial monolayer wound
repair in subjects treated with salbutamol [17].
Experimental studies in animals, and ex-vivo human
lung show that both intravenous and inhaled b adrener-
gic agonists accelerate the rate of alveolar fluid clearance
thus hastening resolution of non-cardiogenic pulmonary
oedema [18]. Evidence of their potential efficacy in
humans was first shown by Sartori et al who used inhaled
salmeterol to prevent the development of high altitude
pulmonary oedema in mountaineers [19]. In patients
with ARDS, the phase II randomised controlled trial
BALTI-1 found that intravenous salbutamol significantly
reduced lung water and improved lung mechanics ARDS
[20].
In summary, the potential of prophylactic administration
of b2 agonists in subjects at high risk of developing ARDS
has not previously been evaluated. Theoretically the
administration of treatment prior to injury has the poten-
tial to reduce the development of lung injury through
decreasing inflammatory cell infiltration, activation and
inflammatory cytokine release, enhancing basal alveolar
fluid clearance and improving alveolar capillary barrier
function. This study aims to define the effectiveness of
inhaled salmeterol (a long acting b2 agonist) for the pre-
vention of ALI/ARDS in a group of subjects at high risk of
developing the condition. The treatment is simple and
known to be well tolerated in people with obstructive lung
diseases and if effective could be easily incorporated into
widespread clinical practice. The results from this trial will
provide the basis for future clinical studies investigating
this and other preventative strategies in broader subject
groups known to be at risk of ARDS (such as pneumonia
and sepsis).
The Beta Agonist Lung Injury TrIal (prevention)
[BALTI-prevention] is a multi-centre, randomised, dou-
ble blind, placebo-controlled trial. The aim of the trial is
to determine in patients undergoing elective transthor-
acic oesphagectomy, if treatment with inhaled salmeterol
10 0mcg twice daily started at induction of anaesthesia
and continued for 72 hours thereafter compared to pla-
cebo affect the incidence of early acute lung injury and
other clinical, resource and patient focused outcomes.
Methods / Design
Trial Approvals and Conduct
The trial is approved by South Birmingham Research
Ethics committee. The trial is registered on the Interna-
tional Standard Randomised Controlled Trial Registry
(ISRCTN47481946). The sponsor organisation for the
trial is Heart of England NHS Foundation Trust. The
trial is being coordinated by the Warwick Clinical Trials
Unit (http://www.warwick.ac.uk/go/ctu). The trial is
funded by the National Institute for Health Research
(NIHR) Research for Patient Benefit Programme (PB-PG-
0408-16104). Further details can be found on the trial
website (http://www2.warwick.ac.uk/fac/med/research/
ctu/trials/ecr/baltiprevention). The trial will be carried
out in accordance with the Medical Research Council
(MRC) Good Clinical Practice Guidelines, applicable UK
legislation and the Standard Operating Procedures of the
Warwick Clinical Trials Unit. The trial will be reported
in line with the Consolidated Standards of Reporting
Trials (CONSORT) 2010 guidelines [21].
Outcome measures
Primary outcome
The primary outcome will be the development of acute
lung injury within 72 hours of oesophagectomy. Lung
injury will be defined by the American European Consen-
sus conference definition [22] as the acute onset of
(1) Bilateral infiltrates on the chest xray (2) Hypoxaemia
with a PaO2 : FiO2 ratio of < 40 kPa (3) absence of clini-
cal evidence of left atrial hypertension. The presence of
absence of ALI will be determined by a trial end-point
committee who will review chest xrays and physiological
data from trial participants. The time window of
72 hours has been selected to exclude ALI/ARDS which
may occur as a consequence of surgical complications
e.g. anastamotic leak, ventilator associated pneumonia
which occur later in the post-operative course.
Secondary outcomes
The trial secondary outcomes are the development of
ALI/ARDS during the first 28 days post operatively;
PaO2 : FiO2 ratio; the number of ventilator and organ
failure free days, 28 and 90 day survival; health related
quality of life and resource utilisation.
Ventilator free days are defined in accordance with the
ARDSnet criteria [23] as the number of calendar days after
initiating unassisted breathing to day 28 after randomisa-
tion, assuming a patient survives for at least 48 consecu-
tive hours after initiating unassisted breathing. Un-assisted
breathing is defined as one of at least 48 consecutive
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hours of (1) being extubated with face mask, nasal prong
oxygen, or room air (2) T-tube breathing (3)Tracheostomy
mask breathing, CPAP = 5 cm H20 without pressure sup-
port of intermittent mandatory ventilation assistance. For
example, if a subject initiates unassisted breathing on day
16 and survives to day 28, he/she will be assigned a value
of 12 VFDs. If a similar subject begins unassisted breathing
on day 16 but dies on day 25, the VFDs is 9. If a subject
survives for >48 consecutive hours of unassisted breathing
but requires assisted breathing (for any reason) before day
28, he/she will be assigned only the number of days of
unassisted breathing before day 28. Subjects who die with-
out initiating unassisted breathing or before 48 consecu-
tive hours of unassisted breathing will be assigned a value
of zero VFDs. Subjects transferred to another hospital or
other health care facility prior to day 28 (intermediate
care, nursing home etc.) while still on positive pressure
ventilation will be followed up to assess this efficacy
measure.
Organ failure free days are defined in a similar manner
to ventilator free days with an organ failure free day being
a day without evidence of non-respiratory organ failure.
Organ failure will be defined as a sequential organ failure
assessment (SOFA) score of greater than 3 [24].
Health related quality of life will be measured using
EuroQol (EQ-5D). Data will be collected at baseline,
28 days and 90 days. Resource utilisation (intensive care
and hospital length of stay) will be recording. The cost
of intervention and resource use will be compared.
Translational sub-study
A translational sub-study will run in a subset of patients
enrolled in the main trial. In addition to the outcomes
above extravascular lung water (PiCCO, Pulsion Medi-
cal) will be measured and bronchoalveoalar lavage fluid
[25,26] and plasma will be collected to measure markers
of inflammation, tissue damage / repair.
Eligibility criteria
Patients will be eligible for the trial if they fulfil the fol-
lowing criteria:
1. Provision of informed consent
2. Age >18 years
3. Planned elective transthoracic oesophagectomy
4. Ability to use inhaler with spacer device
Patients fulfilling any of the criteria below will be
excluded from the trial:
1. Pregnancy
2. Current treatment with long acting beta agonist
(any formulation)
3. Allergy to excipients contained in the salmeterol
inhaler (HFA 134a)
4. Current treatment with non-cardioselective beta
blockers (the cardioselective beta blockers atenolol, beta-
zolol, bisoprolol and metoprolol are permitted).
5. Treatment with an investigational medicinal pro-
duct in the last 30 days.
Power and sample size estimate
A systematic review of the literature noted significant
variability in the incidence of acute lung injury after
oesophagectomy with reports ranging from 14.5 - 43%
[5]. Major studies relevant to the UK population include
the national CEPOD report which quotes an incidence
of 27% [8] and national gastro-oesophageal audit
(ASCOTT) which had an incidence 40.5% [7]. An analy-
sis of 6971 patients from Intensive Care National Audit
and Research Centre (ICNARC) found that 3352 (47%)
fulfilled the oxygenation criteria for ALI in the first 24
hours post operatively [6]. A 5 year audit of oesophagec-
tomies at Heart of England NHS Trust identified that
28% of patients fulfilled criteria for ALI. Based on these
data a conservative estimate of the incidence ALI of
25% was selected.
There are no prospective randomised controlled trials in
oesophagectomy patients to predict the size of the treat-
ment effect of salmeterol for preventing ALI. In the rando-
mised controlled high altitude pulmonary oedema study,
the prophylactic use of salmeterol reduced the incidence of
pulmonary oedema from 74 to 33% (55% relative reduc-
tion) [13]. LPS challenge studies in humans have shown
that salmeterol can reduce neutrophil influx, inflammatory
cytokine production and aberrant coagulation by 40-66%
relative reduction [12,27]. The study originally set out to
demonstrate a 15% absolute reduction in development of
acute lung injury. However the study funders requested in
2009 that the study was re-powered to detect a more mod-
est treatment effect. The size of the treatment effect was
decided following discussions with the British Society of
Oesophageal Gastric Surgeons. Assuming a baseline inci-
dence of lung injury of 25%, consensus was reached that a
treatment effect of at least 12.5% (50% relative reduction)
was necessary to convince clinicians to translate the treat-
ment into clinical practise should the trial demonstrate
that salmeterol prevents ALI/ARDS. This equates to a
number need to treat of eight to prevent one episode of
lung injury.
To demonstrate this effect with 80% power at a sig-
nificance level of 0.05 will require 336 patients. To
ensure the study maintains sufficient power after drop-
outs we have included a 5% failure to proceed to
oesphagectomy / receive one lung ventilation and a
2.4% loss to follow-up rate [28]. This gives an overall
sample size of 180 per arm (figure 1). This sample size
will have 80% power to detect the following relative
risk changes in secondary outcomes at a significance
level of 0.05: PaO2 : FiO2 ratio (10%); critical care
(35%) and hospital (15%) length of stay; HRQL (15%)
and breathlessness(20%).
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Trial conduct
Approach to patients and obtaining informed consent
Patients will be identified through upper GI cancer
teams. Eligible patients will be invited to participate by
their treating clinician, specialist clinical nurse or
research nurse. If agreeable, written informed consent
will be obtained, following a face to face discussion
about the study.
Randomisation and drug / placebo supply
The trial statistician will produce the randomisation
sequence using a block size of 10 with equal allocation
between active and placebo groups. Drug (salmeterol
25 mcg metered dose inhaler) and matching placebo
will be supplied and packaged according to the rando-
misation sequence into numbered treatment boxes by
MODEPHARMA(London, UK). Drug boxes will be sup-
plied in groups of ten to centres thus ensuring an equal
allocation between active and placebo groups to balance
any differences in case mix, pre-operative, operative and
post-operative care between centres. Patients will be
randomised sequentially by allocating them to the next
numbered treatment pack held at the centre.
Drug administration
Subjects will receive either 100 mcg inhaled salmeterol
or placebo via a spacer device within two hours of
induction of anaesthesia and then 12 hourly for
72 hours. The drug will be administered by qualified
medical or nursing staff. Whenever possible, subjects
will be extubated at the end of surgery. Subjects requir-
ing ventilation post operatively will receive 100 mcg of
the drug via an in-line chamber inserted into the
inspiratory limb of the ventilator circuit.
Concomitant medications
The following medications should not be prescribed to
patients for the duration of the clinical study. Long act-
ing beta agonists, non-cardioselective beta blockers (the
cardioselective beta blockers atenolol, betazolol, bisopro-
lol and metoprolol are permitted) or another investiga-
tional medicinal product.
Inhaled or nebulised short acting beta agonists should
be avoided whenever possible, but are permitted in this
trial in the event of severe bronchospasm.
Post randomisation withdrawals and exclusions
Subjects may withdraw from the trial or the trial treat-
ment at any time without prejudice. If a subject with-
draws from the trial treatment, then they will be
followed-up wherever possible and data collected as per
protocol until the end of the trial. The only exception to
this is where the subject also explicitly withdraws con-
sent for follow-up.
Protocol compliance
Compliance with study drug administration will be
recorded in the data collection booklet by the trial team
by cross referencing with the subjects individual trial
drug pack and drug treatment chart.
Blinding / un-blinding
Patients, clinical and research / trial staff will be una-
ware of which arm of the study a patient is allocated.
Active and placebo treatment packs and their contents
will be identical in appearance. The protocol allows for
emergency un-blinding in the event of significant con-
cerns about patient safety. In the unlikely event that un-
blinding is required the local investigator will discuss
with the Chief Investigator. All events will be logged.
Monitoring and reporting adverse events
Balti-prevention is recruiting a population who are
prone to recognized medical and surgical complications.
It is expected that many of the patients will experience
an event that might be seen as a serious adverse event
but is a recognized complication following oesophagect-
omy. Adverse and serious adverse events which are
recognised complications of surgery e.g. medical (pneu-
monia, sepsis) and surgical (chyle leak, anastamosis leak)
will be recorded in the case report form.
Death, other serious adverse events thought to be related
to the study drug or serious unexpected serious adverse
reactions will be reported to the trial co-ordinating centre
and Chief Investigator within 24 hours of becoming aware
of their occurrence who will inform the sponsor and regu-
latory authorities.
Data collection
Data up until hospital discharge will be recorded in each
subject’s Case Report Form (CRF) by hospital staff.
Patients undergoing elective 
oesophagectomy approx
360 year
   
     
Recruited to trial
n=360
   
      
Salmeterol arm
n=180
Placebo arm
n=180
Stratified
by centre
      
Loss to follow up 
n=4
Failure to 
proceed n=8
Loss to follow 
up n=4
Failure to 
proceed n=8
2.4% drop
out
anticipated
5% failure
to proceed
at surgery
     
28 day survival 
n=168
28 day survival 
n=168
Figure 1 Trial flow diagram.
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Most of the data collected will be obtained from the
patients hospital notes. In the unlikely event that a sub-
ject is transferred to another hospital, the study team
will ensure that data collection is completed by the
receiving hospital.
If the subject remains in hospital at 28 or 90 days,
survival at these time points will be recorded by hospital
staff. Mortality after hospital discharge will be obtained
from NHS Statistical Tracing Service (NSTS).
Health related quality of life follow-up at 28 days and
90 days will use face to face interview if the subject is
still in hospital or postal questionnaire. Any subject who
has moved house without informing the trial team will
be traced via the NHS Strategic Tracing Service. The
questionnaire will contain the EuroQoL (EQ-5D) and
resource use questions.
Postal questionnaires will be sent out and collected by
WCTU. Questionnaires that are not returned, will be
chased using a standard protocol involving reminders by
post (2), telephone (2) and if necessary, collection of
core data items by telephone.
Statistical analysis plan
The primary analysis will be based on ‘Intention-to-
treat’ (ITT). In the ITT analyses, patients will be ana-
lysed according to the treatment they were randomised
to, irrespective of the treatment they actually received.
In addition a per-protocol analysis will be conducted.
Patients that did not proceed with planned surgery or
did not receive the pre-operative dose of drug will be
excluded.
Multiple imputation methods will be used to impute
missing data. Prior to an imputation, the data mechan-
isms (MAR - missing at random; NMAR - not missing
at random; MCAR - missing completely at random) will
be assessed to make sure that multiple imputation is
viable. Only data that is validly missing will be imputed.
In the case of multivariate normal data, the multiple
imputation methods assuming normality will be used. In
the case where one cannot assume a distribution of the
data, the ICE (imputation by chain equations) will be
used. The imputed (intention to treat and adherence to
protocol) datasets will be used for sensitivity analyses.
The primary outcome measure will be compared
between treatment groups using a logistic regression
model, with the dependent variable as acute lung injury/
no acute lung injury within 72 hours and the indepen-
dent variables as treatment and other important predic-
tors (e.g. centre and age). An odds ratio measuring the
treatment effect and its 95% confidence interval will be
reported.
Categorical data will be analysed using logistic regres-
sion models, with treatment group as an independent
variable along with other important predictors.
The summary statistics will be based on proportions
and the 95% CI. Continuous data: Continuous data will
be analysed using linear regression models, with treat-
ment group as an independent variable along with other
important predictors. Difference in treatment will be
based on adjusted mean estimates and 95% CI’s. Time
to event data will be analysed using a log-rank test. Any
patients who have not experienced an event at the time
point of interest or withdrawn will be censored. The
proportion experiencing an event over time will be illu-
strated using a Kaplan-Meier curve for each of the treat-
ment groups. The p-values and a hazard ratio with its
95% CI from a Cox proportional hazards model will also
be presented. The proportional hazard assumption
across treatment arms will be checked graphically using
a log-cumulative hazard plot.
Trial organisation / oversight
Trial oversight will be provided by a Trial Steering
Committee (TSC) comprising of investigators, clinicians
and trialists. The TSC will operate within the relevant
WCTU SOP. An independent data monitoring commit-
tee will monitor the safety of participants enrolled in
the trial through regular review of adverse event reports.
An interim analysis of efficacy is not planned.
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